Xiaojun Huang

Xiaojun Huang is an experienced professional in the field of organic chemistry with a strong background in process research and development. Currently serving as Executive Director at Revolution Medicines since April 2019, Xiaojun has held various leadership roles, including Senior Director and Director, Head of Process R&D. Prior to this, Xiaojun worked at Theravance Biopharma US, Inc. from 2011 to April 2019 as Associate Director and Senior Scientist in Process R&D, notably designing kilogram scale GMP synthesis of an HCV NS5A protein inhibitor. Earlier experience includes roles at Roche Palo Alto and Roche Pharmaceuticals as Research Scientist, where multi-kilogram synthesis of APIs was a key focus, and a position at Pfizer as Senior Scientist, contributing to oncology kinase projects. An academic background includes a Postdoc in Organic Chemistry from Stanford University and a Ph.D. from the University of Alberta, complemented by MSc and BSc degrees from Fudan University in Chemistry.